ARQ Wealth Advisors LLC Acquires 17,639 Shares of Johnson & Johnson $JNJ

Key Points

• ARQ Wealth Advisors LLC increased its Johnson & Johnson stake by 432.1% in the first quarter, buying 17,639 additional shares and bringing its total holdings to 21,721 shares valued at about $5.31 million.
• Wall Street sentiment remains constructive, with 20 analysts rating JNJ a Buy and the consensus at “Moderate Buy”; the average price target is $261.26, with several firms recently lifting their targets.
• Johnson & Johnson posted solid quarterly results, reporting $2.70 EPS on $24.06 billion in revenue, both above estimates, while analysts expect full-year EPS of 11.58.

ARQ Wealth Advisors LLC boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 432.1% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 21,721 shares of the company's stock after buying an additional 17,639 shares during the quarter. ARQ Wealth Advisors LLC's holdings in Johnson & Johnson were worth $5,309,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Sierra Capital LLC raised its stake in shares of Johnson & Johnson by 0.5% in the 4th quarter. Sierra Capital LLC now owns 8,144 shares of the company's stock valued at $1,685,000 after acquiring an additional 41 shares in the last quarter. Beaird Harris Wealth Management LLC grew its holdings in Johnson & Johnson by 1.8% during the fourth quarter. Beaird Harris Wealth Management LLC now owns 2,422 shares of the company's stock valued at $501,000 after purchasing an additional 42 shares during the last quarter. Broadleaf Partners LLC raised its position in shares of Johnson & Johnson by 0.6% in the fourth quarter. Broadleaf Partners LLC now owns 7,348 shares of the company's stock valued at $1,521,000 after purchasing an additional 43 shares during the period. Jessup Wealth Management Inc lifted its stake in shares of Johnson & Johnson by 0.6% in the fourth quarter. Jessup Wealth Management Inc now owns 7,574 shares of the company's stock worth $1,567,000 after buying an additional 44 shares during the last quarter. Finally, Plancorp LLC boosted its holdings in shares of Johnson & Johnson by 0.3% during the 4th quarter. Plancorp LLC now owns 15,889 shares of the company's stock worth $3,288,000 after buying an additional 45 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

JNJ has been the topic of a number of research analyst reports. Wells Fargo & Company raised their target price on shares of Johnson & Johnson from $240.00 to $263.00 and gave the company an "overweight" rating in a research note on Wednesday, April 15th. Weiss Ratings lowered shares of Johnson & Johnson from a "buy (b)" rating to a "buy (b-)" rating in a research report on Monday, June 15th. The Goldman Sachs Group upped their price target on shares of Johnson & Johnson from $265.00 to $275.00 and gave the company a "buy" rating in a report on Wednesday, April 15th. JPMorgan Chase & Co. raised their price target on Johnson & Johnson from $250.00 to $260.00 and gave the company a "neutral" rating in a research report on Wednesday, April 15th. Finally, Morgan Stanley boosted their price objective on Johnson & Johnson from $283.00 to $284.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 8th. Twenty analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $261.26.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $253.70 on Wednesday. The firm's 50-day moving average is $238.18 and its 200-day moving average is $233.92. Johnson & Johnson has a 52-week low of $154.80 and a 52-week high of $269.43. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03. The company has a market cap of $610.71 billion, a price-to-earnings ratio of 29.33, a PEG ratio of 2.46 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, topping analysts' consensus estimates of $2.68 by $0.02. The business had revenue of $24.06 billion for the quarter, compared to the consensus estimate of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The firm's revenue for the quarter was up 9.9% compared to the same quarter last year. During the same period last year, the business earned $2.77 earnings per share. Equities research analysts anticipate that Johnson & Johnson will post 11.58 earnings per share for the current year.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Analysts expect Johnson & Johnson to post a solid Q2 print, with commentary pointing to an upbeat report even as Stelara faces headwinds. Johnson & Johnson: Analysts see upbeat Q2 print despite Stelara headwinds
• Positive Sentiment: Several preview pieces say JNJ is trading near all-time highs and could still have more upside if earnings and guidance come in strong. Johnson & Johnson Q2 Preview: Stock Near All-Time Highs, Market Expert Sees Rally to $282
• Positive Sentiment: RBC raised its price target on JNJ to $287 from $265 and maintained an outperform rating, reinforcing bullish sentiment.
• Positive Sentiment: Coverage also highlighted JNJ’s strong year-to-date run and defensive healthcare appeal, which has supported investor demand ahead of earnings. Johnson & Johnson Reports Q2 Earnings Tomorrow. What Investors Should Expect.
• Neutral Sentiment: Other articles focused on JNJ as a dividend and income stock, which may support valuation but did not add new material catalysts. How to earn $500 a month from Johnson & Johnson stock ahead of Q2 earnings
• Negative Sentiment: Some commentary noted the stock’s rich valuation after a big rally, suggesting investors may be paying a premium heading into the report. What Lilly's Peer-Beating Numbers Cost You

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the business's stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the sale, the executive vice president directly owned 114,288 shares in the company, valued at approximately $27,560,551.20. The trade was a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.16% of the company's stock.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.